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Chloroquine-
Resistant 
Plasmodium vivax, 
Brazilian Amazon
To the Editor: Plasmodium vivax 
is the protozoan that causes the second 
most common form of malaria. Some 
resistant strains to chloroquine (CQ) 
occur in a few places in Asia  and the 
Indo-Paciﬁ  c Region (1–4). Although 
resistance of P. vivax to CQ has al-
ready been described in South Ameri-
ca (5–7), there are limited data regard-
ing this issue.
CQ plus primaquine is the stan-
dard treatment for vivax malaria 
worldwide. Presently, this drug regi-
men exhibits satisfactory efﬁ  cacy in 
the Brazilian Amazon. However, in 
recent years several treatment fail-
ures presumably related to CQ resis-
tance, have been reported in the city 
of Manaus (Amazonas) where vivax 
malaria predominates (7). This obser-
vation warrants local attention despite 
these cases having no conﬁ  rmation 
of CQ blood levels  on the basis of 
the appearance of asexual parasites 
against CQ plus desethylchloroquine 
levels exceeding the minimally effec-
tive plasma concentration proposed for 
sensitive parasite strains (>10 ng/mL) 
(8), according to Pan American Health 
Organization recommendations (9).
From September 2004 to February 
2005, a 28-day in vivo test was con-
ducted at the Foundation for Tropical 
Medicine of Amazonas (FMTAM) in 
Manaus, Brazil, to assess the efﬁ  cacy 
of standard supervised CQ therapy. 
The test involved 166 volunteers with 
uncomplicated vivax malaria. Each 
volunteer was administered uncoated, 
scored, 150-mg CQ tablets (10 + 7.5 
+ 7.5 mg/kg at 24-hour intervals) (9). 
Primaquine was withheld until day 
28 (dose regimen of 30 mg/day for 7 
days). Among the 109 volunteers who 
completed the in vivo test, 19 had pos-
itive blood smears within the 28-day 
follow-up (1 on day 14, 3 on day 21, 
and 15 on day 28). All were required 
to undergo alternative therapy (meﬂ  o-
quine). Adequate CQ absorption was 
conﬁ  rmed in these cases on day 2 with 
a mean ± SD CQ plasma concentration 
of 785.4 ± 800.1 ng/mL) (10) Suspect-
ed therapeutic failure (P. vivax CQ re-
sistance) was conﬁ  rmed in 11 (10.1%) 
of 109 persons with a mean isolated 
choloroquine plasma concentration 
>10 ng/mL (356.6 ± 296.1 ng/mL) (9). 
Desethylchloroquine levels in plasma 
were not measured.
Previously, a CQ efﬁ  cacy study 
demonstrated that 4.4% of those test-
ed had CQ-resistant P. vivax ( 7). In 
comparison, the proportion of failures 
(10.1%) in the current study seems to 
be relevant; even though most of the 
P. vivax infections (98, 89.9%) were 
successfully evaluated and adequate 
clinical and parasitologic responses 
were obtained. Currently, the FMTAM 
Manaus Outpatient Clinic is detecting 
patients from different areas of the city 
who show parasitologic recurrences 
after correct treatment within 28 days 
of the routine clinical follow-up. This 
observation is an indirect indicator of 
the possible regional spread of P. vivax 
CQ-resistant strains (unpub. data).
We believe our ﬁ  ndings are im-
portant and merit the attention of 
local public health authorities. Con-
sidering the possibility of emerging 
underestimated  P. vivax CQ resis-
tance in Manaus, we feel it is essen-
tial to quickly clarify whether such 
documented resistance can copromote 
vivax malaria outbreaks in malaria-
endemic areas within the Amazon.
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Avian Inﬂ  uenza 
Risk Perceptions, 
Laos
To the Editor: After the 2004 
outbreak of highly pathogenic avian 
inﬂ   uenza (HPAI) in poultry in Lao 
People’s Democratic Republic (PDR), 
the Ministry of Health implemented 
extensive virologic surveillance (1,2). 
Surveillance began in July 2005, and 
by early 2006, only sporadic cases 
were found. In July 2006, an outbreak 
of HPAI was conﬁ  rmed on 2 chicken 
farms in Vientiane, the capital city of 
Lao PDR (1,3). Most of Laos’ ≈20 
million chickens are kept on family-
owned backyard farms; 3.2 million 
are on commercial farms (4). This 
production meets 80% of Lao poultry 
(chicken, duck, goose, quail) needs; 
imports from neighboring countries, 
either through legal trade or cross-
border smuggling, account for the rest 
(3). Common poultry diseases occur 
frequently during the cold season, and 
lack of reporting of poultry deaths is 
of concern (4).
Until February 2007, no human 
cases of inﬂ  uenza A (H5N1) had been 
reported in Lao PDR. To learn more 
about Laotians’ knowledge of HPAI 
and perceptions of their risk, we con-
ducted a cross-sectional survey.
In March–April 2006, participants 
in 3 settings (Vientiane, urban; Oudo-
mxay, semiurban; Attapeu Province 
and Hinheub District, both rural) were 
interviewed in the Lao language by 
means of a standardized 33-question 
survey. We recorded information about 
behavior, poultry handling and keeping 
practices, and poultry deaths. We used 
multivariate analysis (Stata, version 8; 
Stata Corporation, College Station, TX, 
USA) to analyze the factors associated 
with behavior changes.
Using a random sampling list of 
visitors and vendors, we interviewed 
461 respondents in 4 Vientiane city 
markets (Vientiane has 114,793 
households and 3,700 registered poul-
try farms) (5). Semiurban respondents 
were recruited in Oudomxay (40,987 
households, 715 poultry farms), an ac-
tive trading zone near the Chinese bor-
der. Rural respondents were recruited 
from Hinheup District and in Attapeu 
(19,050 households, 360 poultry 
farms), near the Vietnam border. 
Twenty villages were randomly se-
lected, and 10 participants per village 
were randomly selected for interview. 
Approval for the investigation was 
obtained from the health and market 
authorities. Oral consent for interview 
was obtained from participants.
A total of 842 participants were 
interviewed (Table). Differences in 
occupation and literacy were associ-
ated with different study areas. Differ-
ences in participant sex and age were 
also noted because, in the rural areas, 
interviews took place in the home. A 
total of 583 (69.3%) participants were 
female: 302 (65.5%), 139 (68.2%), 
and 150 (79.3%), in urban, semiur-
ban, and rural areas, respectively; p = 
0.002, 95% conﬁ  dence interval 66–72.   
Mean ages for participants in these ar-
eas were 41 (range 40–43), 34 (range 
32–36), and 38 (range 37–41) years, 
respectively; p<0.001. Animal breed-
ing was conducted by 50% of fami-
lies. Daily close exposure to poultry 
was common (39.6%). Few families 
owned a henhouse, and no special han-
dling of poultry was reported. Rates of 
poultry vaccination against common 
poultry diseases were higher in urban 
and semiurban areas; veterinary sur-
veillance was low (10.2%).
Overall, 96.9% of respondents had 
already heard of HPAI, mainly through 
television. Urban residents ranked it 
as the most well-known poultry dis-
ease, but rural residents ranked it ﬁ  fth. 
Less than half of the respondents had 
some knowledge of the disease signs 
and symptoms for humans and poul-
try; 28.4% could describe 1 symptom. 
Half of the respondents believed that 
they were not at risk for human avian 
inﬂ  uenza or that their poultry were not 
at risk for it. Respondents in urban and 
semiurban areas knew more about avi-
an inﬂ  uenza than those in rural areas.
During the cold season, poultry 
deaths were higher in the north (cold-
er) and south than in Vientiane. The 
poultry mortality rate during the cold 
season was similar to that of Cambo-
dia  (6). Behavior regarding poultry 
deaths differed between areas. Despite 
a high rate of poultry deaths, none of 
the interviewees had notiﬁ  ed authori-
ties. Since hearing about HPAI, 67.1% 